Studies on the Efficacy of rifaximin for covert hepatic encephalopathy - Rifaximin study

Kumamoto University0 个研究点目标入组 60 人开始时间: 2023年2月1日最近更新: 2024年4月23日

试验速览

暂无简介。

•1. Patients with a mental illness (depression, mask depression, schizophrenia, dementia, etc.) 2. Patients diagnosed with malignant tumors and are undergoing treatment or untreated 3. Patients who have any of the following complications: Ascites requiring regular drainage Bleeding due to rupture of esophagus and gastric varicose veins Idiopathic bacterial peritonitis Severe electrolyte abnormalities that affect neuropsychiatric function 4. Patients with a history of hypersensitivity to rifaximin 5. Have serious complications listed below Patients with severe renal impairment or end-stage renal failure under dialysis Patients with uncontrolled conditions such as myocardial infarction, heart failure, angina pectoris, and arrhythmia 6. If a carnitine or zinc preparation is newly administered or the dose is changed between 4 weeks before the administration of rifaximin and 12 weeks after administration. 7. Pregnant women, lactating patients, and patients who may or intend to become pregnant 8. Patients with difficulty taking it orally 9. Other patients that the physician deems inappropriate to safely conduct this study 10. Patients with concomitant use of the following drugs (prohibited drugs: ethinylestradiol, cyclosporine). 11. Patients who have started antibiotics containing rifaximin or proton pump inhibitors within 12 weeks.

发起方